CA2116234C - Use of n-acetyl-l-cysteine and derivatives for regulating skin wrinkles and/or skin atrophy - Google Patents

Abstract

The present invention relates to a method for regulating wrinkles and/or atrophy in mammalian skin comprising treating the skin with a safe and effective amount of N-acetyl-L-cysteine and/or a derivative thereof.

Description

W o g3/0466g PcT/uss2/o72~7 211~2~
~SE OF N-ACETYL-L-CYSTEINE AND DERIYATIVES
FOR REGULATING SKIN WRINKLES AND/OR SKIN AlROPHY

~echnical Field The present invention relates to the field of anti-aging of skin. Specifically, the invention relates to novel compositions and methods of using the compositions for effacing and preventing wri n kl es i n mamlnal i an s ki n .
Back~round of the Invention Skin is subject to abuse by many extrinsic ~environmental) factors as well as intrinsic (chronoaging) factors. A common extrinsic factor is expos~re to ultra~iolet radiatton. Whether extrinsic or intrinsic, the abuse results in wrinkling of the skin. To many people, skin wrinkles are a relninder of the disappearance of you~h. As a result, the elimination of wrinkles has bec~me a booming business in youth-consciaus societies.
Treatments range ~rom cosmetic creams and moisturizers to various forms of cssmetic surgery. :~
Chronoaging results in the thinning and general degradation or skin. As the skin naturally ag~s, there is a re~uc~ion in the cells and blood vessels that supply the skin. There is also a flattening of the dermal-epidermal Junction which results in weaker~ mechanical resistance of this junction. As a consequence~
older pers~ns are more susce:ptive to blister formatian in cases of mechan:ical trauma or:~disease processes. (See Oikarinen. (1990) "The Aging of Skin: Chronoaging Versus Phokoaging", Photodermatal.
hotolmmunol. Photomed., Vol. 7, pp 3-4).
N-acetyl-L-cysteine,~ a:pre~erred active of the present inven-t:ion~ has been used as a muco~ytic, corneal vulnerary and an anti-. .
: dot~: to acetaminophen~ polsonlng (The Merck Index, (1989) 11th : Edition~ p.14:). Euro~ean Patent Application 219 4~. Fabbro, ': :

WO 93/0~66~ PCI'/1~592/072~7 ~116234 published April 22, 1987, discloses a dermatological and skincosmetic, topical, cosmetic composition containing N-acetyl-L-cysteine as the active constituent. The composition is disclosed as being useful for the prevention and treatment of sunburn and for increasing the speed of skin pigmentation bron-~ing.
Obiects of the Present Invention It is an object of the present invenkion to provide a method o~ regulating wrinkles and/or atrophy in mammalian skin which com-prises treating mammalian skin with a safe and effective amount of an anti-wrinklelanti-atrophy agent.
SummarY of the ~nvention The present invention relates to a method ~or r~gulating wrinkles and/or atrophy in mam~alian skin com~rising chronic treatment of the skin with a safe and effective amounk of~N-ace-~ tyl-L-cysteine and/~r a derivati~e thereof.
;~ ~etailed DescriPtion of the Invention As used herein, "alkyl" means an unsubstituted carbon-containing chain which may be straight, branched or cyclic, preferably straight or branched, more preferably straight, saturated, monounsaturated (i.e., one double or triple bond in the chain), or polyunsaturated (i.e., two or more double bonds in the chain; two or more trlple bonds in the chain; one or more dou~le and one or more triple bonds in the chain), preferably saturated.
As used herein, "topical application" means directly laying on or spreading on out~r skin.
As used~herein, "cosmetically-acceptable" means that drugs, medicaments or inert ingredients which the term describes are suitable for use in contact with the tissues of humans and lower animals iwithout undue~toxicity, incompatibility, instability, irritation, allergic~response, and ~he like? commensurate with a reasonable benef;t/risk~ratio.
As used~ herein, "regulat~ing wrinkles" means preventing, retarding, arresting, ;or;reversing the process of wrinkle forma-tion in mammalian skin.~
" ~

~;

WO 93/04669 PCI /US92/0~8~
211 b~3~

As used herein, "skin atrophy" means the thinning and/or general degradatiun of the dermis often characterized by a decrease in collagen and/or elastin as well as decreased number, si~e and doubling potential of fibroblast cells. Skin atrophy is a natural result of aging. Skin atrophy is of~en an undesirable side effect resulting from treatment with corticosteroids.
As used herein, "regulating skin atrophy" means preventing, retarding, arresting, or reversing the process of atrophy in mam-malian skin.
As used herein, "safe and effect1ve amount" means an amcunt of compound or composition sufficient to significantly induce a positiYe m~dification in th~ conditlon to be treated, but low enough to avoid serious side effects (at a reasonab1e benefit/ris~
ratio), within the scope of sound medical judgment. The safe and effective ~mnunt of the compound or compos1tion will vary with the particular oondition being treated, the age and physical condition of the patient be;ng treated, the severity o~ ~he condition, the duration of the treatment, the nature of concurrent therapy, the specific compound or composition employed, the particular cosmetically-acceptable carrier utilized, and like factors within the knowledge and expertise of the attending physician.
As used herein, "chronic treatment" means continued treatm~nt with an active agent over an extended period during a subject's lifetime, preferably for at least absut one month, more preferably from about three months to about twenty years, more preferably from about six months to about ~en years, more preferably still from about one year to about five years As used herein, al~ percentages are by weiyht unless other-wise specified.
Active Comoound The present invention relates to a method for regulating wrinkles and/or atrophy in mammalian skin comprising trca~ing the skin with a safe and effective amount of a composition comprising an active compound. As used herein, "active compound" means a compound having the structure WO (~3/046~9 Z 1 1 6 2 3 ~ PC~/US'32/07287 o~3 I

C - O

R~ C - NH - CH - CH2 - S---R2 or a cosmetically-acceptable salt thereof.
Rl is selected from the group consisting of nil and a Cl-Clg alkyl, preferably Cl-C7, more preferably Cl-C3, more preferably still Cl alkyl.
R2 is selected from the group consisting of nil, -H, Cl-Clg Iq alkyl and -C - R4; pre~erably -H and, Cl-Clg alkyl, more preferably -H. In one embodiment~ R~ is preferably a Cl-Clg alkyl, more preferably Cl-C7, more preferably Cl-C3, more preferablY still Cl.
R3 is selected frnm the group consisting ~f -~ and Cl-Clg alkyl, preferably -H. In one embodiment, R3 is preferably a Cl-Clg alkyl, more preferably Cl-C7, more preferably Cl-C3~ more pre~erably still Cl.
R4 is a C~-Cl~ alkyl; preferably Cl-C7; more preferably Cl-C3; more preferably still Cl. ' ~' In another embodiment, both Rl and R2 are nil and the carbonyl carbon and the su~fur adiacent Rl and R2~ respectively, are covalentl~ bonded to form a cyclic ring. Otherwise, both R
: and R2 are other than nil.
:: :
: ~ Preferred cosmetically-acceptable salts of the active ~ compound include~ but are ~not limited to, sodium, potassium, ! . I ' : I I , ! : ~
magnesium, calcium, lithium, rubidium, strontium, aluminum,~ boron, : silicon and:zinc~ salts of the active compsund.
: In a specific embodiment, the present invention relates to a method for regulating~: wrinkles and/or skin atrophy in mammalian 1 skin comprising treating t he skin~with a safe and effective amount ~: :of N-acetyl-L-cysteine h~ving the structure ~/0 ~3/04669 PCI/U~;9~/07287 211~Z3~
- 5 ~
OH
O C ~ O

Compositions of the present invention comprise from about 0.01% to abaut 5~ of the act~ve co~pound. preferably fro~ about 0.1% to about 2~%, more preferably from about 2% to about 5%.
Zinc Salts In a preferred embod~ment, the compostt10ns af the presQnt invention are rendered substant1ally odorless by addit~on~l~y comprising a zinc sa1t. Without being bound by theory, zinc most likely removes odor by complexing with malodorous H2 which may be formed as trace amo~nts of th~ actiY~ ccmpound decompnses. Zinc salts useful in the present invention include, but are not limited to, the following:
Name Formula Zinc acetate Zn(C2H302)2 Zinc ace~ate-~-water Zn(C2H302)2 H20 Zinc aluminum axide (l/l)(~hnite) A1203 ZnO
Zinc di amide Zn(NH2)2 Linc antimonide ZnlSb2 ~inc arsenate(V)-8-water (koettigite) Zn3~AsO~)2 8~0 Zin~ ars~nate(llI~ : ~ Zn3(Aso2)~2 Zinc arsenate(V)-hydroxide (1/l)(adamite) Zn 3 (AsO~) 2 Zn(OH) 2 : Zinc arsenide ~ Zn~As2 Zinc bro~ate~6-water ~ Zn(BrO3)2-6~0 Z~nc bromide : ZnBr2 Zinc car~onate:(zincspar~ smithsonite) ~n~Ol i Zinc chlorate-4-water: ~ Zn~C103)2 4H20 Zinc ch10ride : ZnC12 Zinc -diammlne:chl~oride : (Zn(NH3)2)C12 Zinc~ chromate(YI~ ZnCrO, ~inc cyanide ~ Zn(CN) 2 Zinc dichr~mate(VI)-3-water ZnCr2 l. ~1~ ~
7inc diphosphate ~ Zn2P2~7 ~: : :: : :

Wo 93/04669 2 1 1 ~ 2 3 4 Pcr/uss2/o72~7 2inc hex~cyanofluoride ferrat~(II) Zn2(Fe~CN)~) Zi nc fl uoride ZnF2 ~inc f1uoride~4-water ZnF2 4H~
Zinc formate Zn(Hcot) 2 Zi nc formate-2 -water Zn ( HCO2 ) 2 2H2 0 Zinc hydroxide In(OH)2 Zinc iodate Zn(IOl)2 Zinc iod~e-2 water Zn~IO~J2 ZH20 Z~nc iod~de Znl2 Zinc i ron oxidQ ( 1/1 ) Fa203 ZnO
Zinc nitra~e 6~water ZntNO~)~ 6H20 Zinc nitride Zn~Nz Zinc oxalate 2-water ZnC204 2~20 Zinc oxide (zincite) ZnO
Zinc perchlorate-6-water Zn~C10~) 2 ' 6H2~
Zinc permanganate-6-water Zn(MnO~ ~ 2 ' 6H2~
Zinc peroxide ZnO2 Zinc p-phenolsulfonate-8-w~ter Zn(c~H~(oH)so3)2 8H20 Zinc phosphate(V) Zn~ ~P~~ ) 2 Zinc phosphate-4-water (hopeite) Zn3(PO4)2 4~20 Zinc phosphide Zn3P2 Zinc propionate Zn~c3H5o2)z t Zinc selanate(VI)-S-water ZnScO~ 5 Zinc se1enid~ ZnSe Zinc si1icate(2-) ZnSiO7 Zinc silicate:(4-) (willemite? Zn2SiO4 Zinc silicon oxide-water (211/1) 2ZnO SiO2 H20 (hemimorphite) Zinc hexafluoro-si1 t cate-6-water Zn(SiF~3 6~20 Zinc stearat@ 2n(ClJH3s~2)2 Zinc sulfate (~inkosite) ; ZnS04 Zinc sulfate-~-wate~ (goslarite) ZnSO,-7H20 Zinc sul~ide (~) (wurtzite) ZnS
Zinc sulfite-2-water ZnSO9 2H20 Zinc telluride ZnTe Wo 93/04669 pcT/uss2~o72~7 21~2?4 Z i nc th ~ ocyanate Zn ~ SCN ~ 2 Zinc sal~ of th2 active compound ~Zn+23(antt-wrinkle agent) Preferably, thz zinc salt is selected from the group con~
sisting of zinc oxide, zinc ch7Orid~, zinc acetate~ zinc stear~te, and zinc sulfate; more preferahly zinc oxide and zinc chlorid~;
more pr~ferably still, zinc oxide.
Compositicns of the present inventton prefer~bly oGmprise from about .0017. to about 10% af a zinc s31t, more preferably from about û.01~ to about SY~, more preferably still from about 0.1% to abo~lt 0.5%.
Compositions of the present in~ention may comprise a zinc salt of the acti~e compound such as the zinc mercaptide N-acetyl-cysteine oarboxylate salts disclosed in U.S. 3,749,779, Martin, issued July 31, 1973~ incorporated herein by ref~rence.
Zinc complexes which may be forlTed by zinc and th~ active compound a~e useful in th~ co~positions and methods of the present i nventi on .
In addition to its wrinkle and skin atrophy regul~t1ng benefits, the active compound is also useful as a pho~oprotec~ion agent.
Cosmetic ComD~sitions In a preferred em~odiment, treatment will employ the use of a topical ccsnletic composition comprising the actjve compound and a cosmeti cal 1 y - acceptabl e carri er . The tenn " cosmeti cally- acc~ptabl e carrier", as used herein, means one or mcre compatible sol id ~ or l iquid filler diluents or microenca~su-lating substances which arc suitabl~ for administration to a hu~an or lower animal. Cosmetically-acceptable carriers must be of sufficiently high purtty and sufficiently low toxicity to render them suitable for administration to the human or lower animal belng :treated. A safe and effective amount of carrier is from abQut 50Z to about 99.99%, preferably from about 99.9% to about 8~%. m~re preferably from about 9~% to about 95X" of the composit~on.

W o 93/04669 2116 2 3 ~ PCT/US92/07287 Variations in formulation of these carriers will result in a wide variety of products which fall within the scope of the pre-sent invention.
The topical cosmetic compositions of the present invention may be made into a wide variety af product types. These include, but are not limited to lations, creams, beach oils, gels, sticks, sprays, ointments, pastes, mousses and cosmetics~ ~hese product types may comprise several types of carrier systems including, but not limited to s~lutions, emulsions, gels and solids.
The topical cosmetic compositions of the present invention formulated as solutions typically include a cosmetically-acceptable aqueous or organic solvent. The terms "cosmetically-acceptable aqueous solvent" and "cosmetically-acceptable organic solvent" refer to a solvent which is capable of having dispersed or dissolved therein the active compound, and possesses açceptable safety properties (e.g., irritation and sensitization characteristics). Water is a typical aqueous solvent. Examples of suitable organic solvents include: propylene glycol, butylene glycol 7 polyethylene glycol ~200-600), poly-propylene glycol (425-Z025), glycerol, 1,2,4-butanetriol, sorbitol esters, 1,2,6-hexane~riol, ethanol~ isopropanol, butanediol, and mixtures thereof. Preferably, these solutions contain from about 0.01~h to about 50% of the ~ctive compound, more preferably f~om about 0.1% to about 20%; and from about 1% to abou~ 10% of an acceptable aqueous or organlc solvent, more preferably from about 1% to about S%
If the~topical cosmetic compositions of the present invention are formulated as an aerosol and applied to the skin as a spray-on, a propellant is added to a solution compositisn. Examples of propell~nts useful herein include, 'but are not l;mited'to, the chlorinated, fluorinated and chloro-fluorinated lower molecular .
weight hydrocarbons. ~ A more complete disclosure of propellants useful herein can be found in Sagarin, Cosmetics Science and Technoloqv 2nd Editlon, Vol. 2, pp. 443-465 (1972).

:~

Wo 93/~4669 Pcr/U~9~/0~287 2 ~ 1 6 '~
g Topical cosmetic compositions of the present invention may be formulated as a solution comprising an emollient. An example of a composition ~ormulated in this way would be a beach oil product.
Preferably, such compositions contain from about 0.1% to about 50%
of the active compaund and from abouk 2Yo to about SOYO of a topical cosmetically-acceptable emollient.
As use~ herein, "emollients" refer to materials used for the prevention or rel;ef of dryness, as well as for the protection of the skin. A wide variety af suitable emollients are known and may be used herein. Sagarin, Cosmetics. Science and Technolo~, 2nd Edition, Vol. 1, pp. 32-43 (1972), incorporated herein by refer-ence, contains numerous examples of suitable materials.
A lotion can be made from a solution carrier system. Lotions preferably comprise from about 0.1% to abcut 20%, more preferably from about 2% to about 5%, of the active compound; from ab~ut lX
to about 20%, preferably from about 5% to about 10%, of an emollient; and ~rom abo~t 50% to abo~t 90%, preferably from about 60% to about 80%~ wat~r.
Another type of product that may be formulated from a solution carrier system is a cream. A cream of the present invention would pre~erably comprise from about .1% to about 20~, more preferably from about 270 to about 5%, of the act~Ye compound;
from about 5% to about 50%, ~preferably from about 10% to ab'out 20%~ of an emollient, and from~about 45% to about 85%, preferably from about 50% to about 7S%, water.
Yet another~type of:product that may be formulated from a solution carrier system ~is an ointment. An ointment may comprise a simple base of animal or vegetable oils or semi-solid hydro-carbons (oleaglnous). Ointments may also comprise absorption ointment bases which absorb water to form emulsions. Ointment carriers may also be wa~er soluble. An ointment may also comprise from about 2% to about 10% of an emol:lient plus from about 0.1% to about 2% of a thic~kening agent. A more complete disclosure of thickening agents useful herein can be found in Segarin, :
:

WO 93/04~69 2 1 1 6 ~ ~J ~ PCr/US92/~7287 Casmetics, Science and Technulo~Y, 2nd Edition, Vol. 1, pp. 72-73 (1972).
If the carrier is formu1ated as an emulsion, from about 1% to about 10%, preferably from about 2% to about 5%, of the carrier system comprises an emulsifier. Emulsifiers may be nonionic, anionic or cationic. Suitable emulsi~icrs ar~ disclosed in, for example, U.S. Patent 3,755,560, issued August Z8t 1973, Dickert et al; U.S. Patent 4,421,769, issued December 20, 1983, Dixon et al.;
and McCutcheon's Deterqents and Emu1si~lers~ Horth American Edition, pages 317-324 (1986); the disclosures of which are incorporated herein by reference. Preferred emulsifiers are anionic or nonionic~ although the other types may also be used.
Lotions and creams can be formulated as emulsions as well as solutions. Preferably such lotions comprise from about 0.1% to about 20%, more preferably from about 2% to about S%, of the active compound; from about 1% ~o about 20X, preferably from about 5% to about 10%, of an emollient; from about 25% to about 75%, preferably from about 45% to about 95~fi, water; and from about 0.1%
to about 19%, preferably from about 0.5% to about 5%, of an emulsifier. Such creams would preferably comprise from about 0.1%
to about 20%t more preferably ~rom about 29/o to about 5%, of the active compound; from about 1% to about 20Y4, preferably from about 5% to about 10%. of an emollient; from about 20% to about 80~t preferably from :about 30% to about 70%, water; and fr~m about 1%
to about 10%~ preferably from about 2% to about 5%? of an emulsi-fier.
Single emulsion sl~in care preparations, such as lotions and creams, of the oil-in-water type and water-in-oil type are well-known in the cosmetic art and are useful in the present invention.
Multipha~e emulsion compositions, such as the water-in-oil-in-water type, as disclosed in U.S. :Patent No. 4,254,105~ Fakuda et al., issued March 3, 1981, incorporated herein by reference9 are also useful in the present invention. In general, such single or multiphase emulsions contai:n water, emollients and emulsifiers as essential ingredients.

W V 93/04669 PCT/USs~/07287 2 ~ ~ ~

Triple emulsion carrier systems comprising an oil-in-water-in-silicone fluid emulsion composition as disclosed in U.5. Patent No. 4,960,764, Figueroa, issued October 2, 1990, are also useful in the present invention. Preferably, this triple emulsion carrier system can be combined with from about 0.1~h to about 20%, more preferably fram abc~t 2% to about 5YO, of the active compound to yield the topical cosmetic composition of the present invention.
An~ther emulsion carrier system usefu1 in the topical cosmetic compositions of the present invention is a micro-emulsion carrier system. Such a system comprises from about 9% to about 15% squalane; from about 25% to ~bout 4~% silicone oil; from about 8% to about 20% of a fatty alcohol; from about 15% to about 30~ of polyoxyethylene sorbitan mono-fatty acid (commercially available under the trade name Tweens) or other nonionics; and from about 7%
to about 20'~o water. This carrier system is preferab1y combined with from about 2% to about 5% o~ the active compound.
If the topica7 cosmetic compositions of the present invention are formulated as a gel or a cosmetic stick, a suitable amount of a thickening agent, as disclosed ~ , is added to a cream or lotion ~ormulation.
The topical cosmetic campositions o~ the present invention may also be formulatad as makeup products such as fo~ndations.' : The topical cosmetic compositions of the present invention may contain, in addition to ~he aforementioned components, a wide vari ety of addi ti onal oi 7 - so1 ubl e materi al s and~or water- sol ubl e materials conventionally used in topical compositions, at their art-establ i shed 1 evel s .
Various water-soluble materials may ~lso be present in the compositions of this invention. These include humectants, proteins and polypeptides, preservatives and an alkaline agent.
In addition~ the topical compositions herein can contain conven-tional cosmetic adjuvants, such as dyesl opacifiers (e.g., titanium dioxide), pigments and perfumes.

WO 93/~4669 ~ 1 1 6 2 3 ~1 PCI'/US9~/07287 The topical cosmetic compositions of the present invention may also include a safe and effective amount of a penetration enhancing agent. A preferred amount af penetratlon en~ancing agent is from about 1% to about 5% of the composition. E~amples of useful penetration enhancers, among others, are disclosed in U.S. Patents 4,537,776~ ~oopert issued August 27, 1985; 4,552,872, Cooper et al,, issued November 12, 1985; 4,557~934, Cooper, issu~d Oecember 10, 1985; 4,130,667~ Smith, issued ~ccember 19, 1978;

3,989,816, Rhaadhyaksha, issued November 2~ 1976; 4,017,641, DiGiulio, issued April 12, 1977; and European Patent Application 0043738~ Cooper et al., pu~lished January 13~ 1982.
Other conventional skin care prcduct additives may also be included in the compositions of the present invention. For example, csllagen, hya1uronic acid, elastin, hydrolysates, prim-rose oil, jojoba oil~ epidermal growth f~ctor, soybean saponins, mucopolysaccharides, and mixtures thereof may be used.
Various vitamins may also be included in the compositions of the present invention. For example, vitamin A, and d2rivatives thereof, vitamin B2, biotin, pantothenic, vitamin D, vitamin ~, and mixtures thereof may be used4 Cleaninq ComDositiQns The skin cleaning compositions of the present invention comprise, in addition to the actiYe compound, a cosmeticalty-acceptable sur~actant. The term "cosmetically-acceptable sur-factant" refers to a surfactant which is not only an effective skin cleanser, but also can be~ used without undue toxicity, irritation, allergic response, and the like. Furthermore, the surfactant must be capable of being commingled with the active co~no~nd in a manner su~h that ther~ is no interaction which wou7d substantially reduce the :efficacy of the compositisn for regulating skin wrinkles and/or skin atrophy.
., The skin cleaning compositions of the present invention preferably contain from about: 0.1% to about 20%, preferably from about 2% to aboue 5%. of thF active compound and from about lX to ::

W~ 93/~4669 PCI/lJS92/~7287 Z 3 ~

about 90%, more preferably from about 5% to about 10%, of a cosmetically-acceptable surfactant.
The physical form of the skin cleansing compositions is not critical. The compositions can be, for example, formulated as toilet bars, liquids, pastes, or mousses. Tollet ba~s are most preferred since this is the form of cleansing agent most commonly used to wash the skin.
The sur~actant component of the compositions of the present invention are selected from anionic, nonionic, zwitterionic, amphoteric and ampholytic surfactants, as well as mixtures of these surfactants. Such surfactants are well-known to those skilled in the detergency art, The cleaning compositions of the present invention can optionally contain, at their art-established levels, materials which are conventionally used in skin cleansing compositions.
Combination Actives A. Sunscreens and Sunblooks Optimum regulation of skin wrinkling resulting from exposure : to U.V. light can be obtained by using a combination of the active compound of the pressnt invention together with sunscreens or sunblocks. Use~ul sunblocks include, for examplë, zinc oxide and titanium dioxide.
:
Photodamage is a predominant ca~se of skin wrinklin~. Th~s, fo~ purposes of wrinkle prevention, the combination o~ the active compound with a UVA and/or UVB sunscreen would be most desirable.
The inclusion of sunscreens in compositions of the present in~entiun will provide lmmediate protection against acute UV
damage. Thus, the sunscreen will prevent further wrinkle forma-tion caused by UV radiation, while the active compound regulates existing wrinkles and skin atr~ophy.
: A wide~: variety~ of conventional sunscreening agents are suitable for use in: ~ c ambination with the active compound.
:
~: Segarin, et: al.:, at Chapter VIII,: pages 189 et seq., of Cosmetics Science and Technoloqv~, disclose numerous suitable agents.
Specific suitable~ ~ sunscreening agents include, for example:

WO g3/04669 PCI/US9~/07287 21~6~34 p-aminobenzoic acid, its salts and its derivatives (ethyl, iso-butyl, glyceryl esters; p-dimethylaminobenzoic acid); anthrani-lates (i.e., o-aminobenzoates; methyl, menthyl, phenyl, benzyl, phenylethyl, linalyl, terpinyl, and cyclohexenyl esters); sal-icylates (amyl, phenyl, benzyl, menthyl, glyceryl, and dipro-pyleneglycol esters); cinnamic acid deriYatives (methyl and benzyl esters, ~-phenyl cinnamonitrile; butyl cinnamoyl pyruvate);
Dihydroxycinnamic acid derivatiYes (umbelliferone7 methylumbell~-ferone, methylaceto-umbelliferone~; trihydroxycinnamic acid derivatives (esculetin, methy1esc~1etin, daphnetin, and the glucosides, esculin and daphnin); hydrocarbons (diphenylbutadiene, stilbene); dibenzalacetone and benzalacetophenone; Naphthol-sulfonates (sodium salts of 2-naphthol-3.6-disulfonic and of 2-naphthol- 6,8-disulfonic acids~; Dihydroxy-naphthoic acid and its salts; o- and p-Hydroxybipheny1disulfonates; Coumarin derivatives (7-hydroxy, 7-methyl, 3-phenyl ); Diazoles (2-acetyl-3-bromo-indazole, phenyl benzoxazole, methyl naphthsxazole, various aryl benzothiazoles); Quinine salts (bisulfate, sulfate, chloride, olea~e, and tannate); Quinoline~ derivatives (8-hydroxyquinoline salts, 2-phenylquinoline);~Hydroxy- or methoxy-substituted benzo-phenones; Ur~ic and vilouric acids; Tannic acid and its derivatives (e.g., hexaethylether); (Butyl carbotol) (6-propyl piperonyl) ether; Hydroqyinone; Benzophenones (Oxybenzene, Sulisobenzone, Dioxybenzone, Benzoresorcinol~, 2,2',4,4'-TetrahydroxYbenzophenonet 2,2'-Dihydroxy-4,4'-dimethoxybenzophenone, Octabenzone; 4-Iso-propyldibenzoylmethane;~::Butylmethoxydibenzoylmethane; Etocrylene;
and 4-isopropyl-di-benzoylmethane.
Of these, 2-ethylhexyl-p-methoxycinnamate, 4~4'-t-b~tyl methoxydibenzoylmethane, ~2-hy~roxy-4-methoxybenzophenone, octyl-dimethyl-p-aminobenzoic :acid, ~iga110yltrialeate, 2,2-di'hydroxy-4-methoxybenzophenone~ ethyl-4-[bis(hydroxypropyl)]aminobenzoate, 2-ethylhexyl-2-cyano-3,3-diphenyl~aerylate, 2-ethylhexylsalicylate, glyc~eryl-p-ami~nobenzoate~ : 3,3,5-trimethylcyclohexylsalicylate, :
:methylanthra~nilate~, p-dimethylamino-benzoic acid or aminobenzoate, : 2-ethylhexyl-p-dimethylamino-benzoate, 2-phenylbenzimidazole-5-; ~ :; , W~ 93/04669 PCT/U~9~/~7287 211623~

sulfonic acid, Z-(p-dimethylaminophenyl)-5-sul~onic~enzoxazoic acid and mixtures of these compounds, are particularly useful.
Preferred sunscreens useful in the compositions of the present invention are 2 - ethylhexyl-p-me~hoxyci nnamate, butyl -methoxydi benzoyl methane~ 2-hydroxy-4-methoxybenzophenone, octyl-dimethyl-p-aminobenzoic acid and mixtures thereof.
A safe and effective amount of sunscreen may be used in the compositions of the present invention. The sunscreening agent must be compatible with the active compound. Generally the composition may comprise from about 1% to about 20%, preferably from about 2% to about 10%, of a sunscreening agent. Exact amounts will vary depending upan the sunscreen chosen and the desired Sun Protection Factor (SPF~.
Also particularly useful in the present invention are sun-screens such as those disclosed in Sabatelli, U.S. Patent Ap-plication Serial No. 054,085 ~filed June 2, 1987) and Sabatelli et al., U.S. Patent Appl;cation Serial No 054,046 (filed June 2, 1987). The sunscreening agents disclosed therein have, in a single molecule, two distinct chromophore maieties which exhibit different ultra-violet radiation absorption spectra. One of the chromophore moieties absorbs predominantly in the UVB radiation range and the other absorbs strongly in the UVA radiation range.
Preferred.members of this class of sunscreening agents are N,N-(2-ethylhexyl)me~hylaminobenzoic acid ester -of 2,4-di-hydroxybenzophenone; N,N-di-(2-ethylhexyl)-4-aminobenzoic acid ester with 4-hydroxydibenzoylmethane; 4-N,N-(2-ethylhexyl) methyl-aminobenzoic ~acid ester with 4-hydroxydibenzoylmethanei 4-N,N-(2-ethylhexyl~)methylaminobenzoic acid ester of 2-hydroxy-4-(2-hydroxyethoxy)benzophenone; 4-N,~N-(2-ethylhexyl~-methylamino-benzoic acid ester o~ 4-(2-hydroxyethoxy)dibenzoylmethane; N,N-di-;(2-ethylhexyl~-4-aminobe~nzoic acid ester of 2-hydroxy-4-~2-hydroxyethoxy)benzophenone; and M,N-di-(2-ethylhexyl)-4-amino-benzoic acid ester ~of 4-(2-hydroxyethoxy~dibenzoylmethane and ~mixtures thereof.
(*~ equivalent to EP Patent 0251398 granted 12 August 1992 and EP
Patent 0255157 publlshed 03 February 1988) W0 93/~4669 2 1 1 6 2 3 ~ Pcr/US92/07287 An agent may also be added to any of the compositions of the present invention to improve the skin substantivity of those compositions, particularly to enhance their resistance to being washed off by water7 or rubbed off. A preferred agent which will provide this benefit is a copolymer of ethylene and acrylic acid.
Compositions comprising this copolymer are disclosed in U.S.
Patent 4,663,157, Brock, issued May 5, 1987, which is incorporated herein by reference.
B. Anti-In~lammator~ Aqents In a prefarred wrinkle and atrophy regulating composition of the present invention, an anti-inflammatory agent is included as an active agent along with the active compound. The inclusion of an anti-inflammatory agent enhances the wrinkle regulating benefits of the compositions. The anti-inflammatory agent protects strongly in the UYA radiation range (though tt also provides some UVB protection as well) thereby preventin~ further wrinkle formation caused by UV radiation, while the active compound regulates existing wrinkles and skin atrophy. Thus the combination provides broad protection. ~he topical use of anti-inflammatory agents reduces photo-aging of the skin resulting from chronic exposure to UV radiation. ~See U.S. Patent 4.847,071, Bissett, Bush, and Chatterjee, issued July 11, l~89, incorporated herein by reference; and U.S. Patent 4,847,069, Bissett and Chatterjee, issued July 11, 1989, incorporated herein by reference.) A safe~and effective amount of an anti-inflammatory agent may be added to the compasitions of the present invention, preferably from about 0.I% to about 10%, more preferab1y from about 0.5% to about 5%, of the ; composition. The exact amount of anti-inflammatory agent to be used in the compositions will depénd on the parti ular anti-in~lammatory agent utilized since such agents vany widely in potency.
Steroidal anti-lnflammatory agents, including but not limited to~ corticosteroids such as hydrocortisone, hydroxyltriamcino10ne7 alpha-methyl dexamethasone~ dexamethasone-phosphate~

, beclomethasone dipropionate, clobetasol valerate, desonide.
desoxymethasone, desoxycorticosterone acetate, dexamethasone, dichlorisone, diflorasone diacetate, diflucortolone val2rate, fluadrenolone. fluclorolone acetonide, fludrocortisone, flumethasone pivalate, ~luosinolone acetonide, fluocinonide, flucortine butylester, fluocortolone, fluprednidene (fluprednyli-dene) acetate, ~lu~andrenolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triam-cinolone acetonide, cortisone, cortodoxone, flucetonide, fludro-cortisone, difiuorosone diacetate, fluradrenolone acetonide, medrysone, amcinafel, amcinafide, betamethasone and the balance of ;ts esters, chloroprednisone, chlorprednisone acetate, cl~cort-elone, clescinolone, dichlorisone, difluprednate, fluclor'ontde, flunisolide, fluoromethalone, fluperolone, ~luprednisolonei hyd:rocortisone valera'te, hydrocortisone cyclopentylpropionate, hydrocortamate, meprednisone, paramethasone, prednisolone, prednisone, beclomethasone dipropionate, . triamcinolone, and mixtur~es thereof may be used. The preferred steroidal anti-.
inflammatory for use in the~present invention is hydr'ocortisone.
A second class of anti-inflammatory agents which is useful in the composltions of the present' invention includbs the non-~steroidal anti~inflammatory a~ents. The va~iety of compounds encompassed by :this' group are well-kn~wn to those skilled in the .
' art. For detailed disclosure o'f the chemical structure, syn~
: thesis:, side effects, etc.~,: of non-steroidal anti-infl'ammator~
: agents,.~eference may be~had to standard texts, .including Anti-, ~
inflammatory and :Anti-Rheumati.c Oruqs, K~ 0. Rainsford, Vol.
CRC~ pFes~s~ 80ca~ Raton, ~1985), and Anti-inflammatorY
~i ' ' A~ents. ChemistrY and Pharmacoloqy, 1, R. A. Scherrer, et al., :: Academlc- Press, New York~(1974).~: ' :Specific non-steroidal~a'nti-~infiammatary agents useful in the : composition of'.the present inv:ention include, but are not limited to: : :
1) the oxicams, such as ~:piroxicam, isoxicam, tenoxicam, and sudoxicam;: ~ ~ ~

~ITUTE ~3HEET

W o 93/0466~ 2 1 i 6 ~ ~ ~ PC~/US92/07~87 2~ the salicylates, such as aspirin, dis~lcid, benorylate, trilisate, safapryn, solprin, diflunisal. and fendosal;
3) the acetio acid derivatives, such as diclofenac, fen-clofenac, indomethacin, sulindac, tolmetin, isoxepac, furofenac, tiopinacS zidometacin, acematacin, fentiazac, zomepiract, clidanac~ oxepinac, and felbinac;
4) the fenamates, such as mefenamic, meclofenamic, flu-fenamic, niflumic, and tolfenamic acids;

5) the propionic acid derivatives, such as ibuprofen, naproxen, benoxaprofen, flurbiprofen~ ketopro~en, fenoprofen, fenbufen, indoprofen, pirprofen, carprofen, oxaprozin, p~anoprofen, miroprofen, tioxaprofen, supro-fen, alminoprofen, and t1aprofenic; and 6) the pyrazoles, su~h as phenybutazone, oxyphenbutazone, feprazone, azapropazone~ and trimethazone.
Mixtures of these non-steroidal anti-inflammat~ry agents may also be employed, as well as the cosmetically-acceptable salts and esters of these agents. For example, etofenamate, a flufenamic acid derivative, is particularly useful for topical appl ication.
0~ the nonsteroidal anti-inflammatory agents, ibuprofen, naproxen, flufenamic acid, mefenamic acid~ meclofenamic acid, piroxi~am and felbinac are preferred; ibuprofen, naproxen, and flu~enamic acid are most preferred.
Another class of anti-in~lammatory agents which are useful in the present i nvsnti on are ~he anti - i nfl ammatory agents di scl osed in U.S. Patent No. 4,708,966? Loomans et al., issued November 24, 1987. This patent discloses a class of nonsteroidal anti-inflammatory compounds which oomprise specifically substituted ;phenyl eompounds, especially substltuted 2,6-di- tert-butyl phenol derivatives. For example, compounds selected from 4 -(4'-pentyn-3'-one) 2,6-di~t-butylphenol; 4-[5'-hexynoyl)-2,6-di--t-butylphenol; 4-((S)-( )-3'-methyl-5'-hexynoyl)-2.6-di-t-butyl-phenol; 4-((R)-(~)-3'-methyl-5'-hexynoyl)-2,6-di-t-butylphenol;
and 4-~3',3'-dimethoxypropionyl)-2,6-di-t-butylphenol are useful in the present :invention.

~:~

WO 93/0466g P~IU~;92/072~7 21:~23~

Yet another class of anti-inflammatory agents which are useful in the present inv~ntion are those disc)osed in U.S. Patent No. 4t~12,248. Mueller, issued M~rch 27, 1990. This patent dis-closes compounds and diastereomeric mixtures of specific 2-naphthyl- containing ester compounds, especially naproxen ester and naproxol ester compounds, having two or more chiral centers.
For example, compounds selected from (S)-naproxen-(S)-2-butyl ester, (S)-naproxen-(R)-2-butylester~ (S)-naprnxol-{R~-2-methyl butyrate~ (S)-naproxol-(S)-2-methyl butyrate, diasteromeric ~ixtures of (S)-naproxen-tS)-2-butyl ester and (S)-naproxen-(R)-2-butyl ester, and diasteromeric mixtures of (S)-naproxol-(R)-2-methy1 butyrate and (S~-naproxol-(S)-2-me~hyl butyrate are useful in the present invention.
Finally, so-called "natural" anti~inflammatory agents are useful in the present invention. For example~ candelilia waxS
alpha bisabolol, aloe vera, Manjistha (extracted from plants in the genus Rubia, particularly Rubia Cordifolia), and Guggal (extracted from plants in the genus CommiPhora, particularly Commiphora Mukul), may be used.
Anothe~ preferred composition of the present invention comprises the active compound, a s~nscreen, and an anti-inflam-matory agent together for wrinkle and/or atrophy regulation in the amounts disclosed for each individually hereinabove.
C. Anti-Oxidants/Radical Scavenqers In a pre~erred wrinkle and atrophy regulating composition of the present invention, an~ anti-oxidant/radical scavenger is included as an active agen~ along with the active compound. The inclusion of an anti-oxidant/radical scavenger increases the wrinkle Iregulating benefits o~ th~ composition.
A safe and effective amount of an anti-oxidant/radical scavenger may be added to the compositions o~ the present inven-tion, preferably from about 0.1% to about 10%t more preferably from about 1% to about 5%, of the composition.
Anti-oxidants/radical scavengers such as ascorbic acid (vitamin C) and its salts,~ ~ocopherol (vitamin E), tocopherol WO 93/04669 PCTlUS92/07~87 21162~

sorbate, other es~ers of tocopherol, butylated hydroxy benzoic acids and their salts, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (commercially available under the tradename Trolo ~ , gallic acid and its alkyl esters, especially propyl gallate, uric acid and its salts and alkyl esters, sorbic acid and its salts, the ascorbyl esters of fatty acids, amines ~e.g., N,N-diethylhydroxylamine~ amino-guanidine), sul~hydryl compounds (e.g., glutathion~), and dihydroxy fumaric acid and its salts may be used.
In a preferred wrinkle regulating composition of the present invention7 c~mpositions comprise one, any two, or all three of a sunscreening agent. anti-inflammatory agent, and/or an anti-oxidant/radical scavenging agent included as actives along with the active compound. The inclusion of two or all three of these agents with the active compound increases the wrinkle regu7ating benefits of the composition.
O. Chelators In a preferred wrinkle and atrophy regulating composition of the present invention~ a chelating agent is included as an active agent along w1th the active compound. As used herein, "chelating agent" means an active agent capable of removing a metal ion from a system by forming a camplex so that the metal ion cannot readily participate in or catalyze chemica1 reactians. The inclusion o~ a chelating agent increases the wrinkle regulating ben~fits of the composition. ~
A safe and effective amount of a chelating agent may be added to the compositions o~ the ~present invention, preferably from about O.1% to ~about 10%,~more preferably from about 1% to about 5%~ of the composition. Chel~ators useful in compositions of the present in~éntion are disclosed in U.S. Patent Application Sèrial No. 251,910*~Bissett, Bush & Chat~erjee, filed October 4, 1988, incorporated here~ln by reference. Preferred chelators useful in compositions ~of ~ the present invention are furildioxime and deriYatives thereof, more preferably amphi-2-furildioxime.
(* equivalent to EP Patent 0313305 published ~6 April 1989) :

W O 93/0~669 Pcr~us92/o7287 211623~

In a preferred wrinkle and atrophy regulating composition of the pr~sent invention, compositions comprise one, any two, any threet or all four of a sunscreening agent~ anti-inflammatory agent, anti-oxidant/radical scavenging agent, and/or chelating agent included as actives along with the active compound. The inclusion of two, three, or all four o~ these agents with the active compound incrcases the wrinkle regulating benefits of the composition .
E. Retinoids In a preferred wrinkle and atrophy regulatlng composition of the present invention7 a retinoid, preferably retinoic acid, is included as an active agent along with the ~ctive compound. The incl~slon of a retinoid increases th~ wrink1e regulating benefits of the composition. A safe and~effective amount of a retinoid may be added to the compositions of the present in~ention, preferably from about 0.001% to about 2%, more preferably from about 0.01% to about 1% of the composition. As used herein, "retinoid" includes all natural and/or synthetic analogs o~ Vitamin A or retinol-like compounds which possess the bio1Ogical activity of Vitamin A in the skin as well as the geometric isomers and stereoisomers of these compounds, such as all-trans retinoic acid and 13-cis-retinoic acid.
F. Benzofuran Derivatives : In a preferred wrinkle and atrophy regulating composition of the present invention, a benzofuran derivative, preferably amiodarone, is included as an active agent along with the active compound. The inclusion of a benzofuran derivative increases the wrinkle regulating benefits of the eomposition.
A~safe and effective amount of a benzofuran derivative may be added to the compositions of the present invention, preferably ; ~from about 0.01% to about 20%~,~more preferably from about 0.1% to about 10%, Qf the composition. Benzofuran derivatives useful in the present invention~ are~disclosed in U.S. Patent A~plication Serial No. 674,628* Chatterjee and Kapoor, filed March 2~, 1991, incorporated herein by reference.
(*equivalent to US Patent ~5,118,707 granted 02 June 1992) :

WO 93/0466~ PCI/USg2/07287 21~6~3~
.~.
- ~2 -In a preferred wrinkle regu1ating composition of the present invention, compositions comprise one, any two, any three, any fours~ any fivse~ and or all six of a sunscreening a~ent, anti-in-flammatory agent, anti-oxidant/radica1 scavenging agent, chelating agent, retinoid, and/or benzofuran derivative included as actives along wi~h the active compound. The inclusion of two, three, four, fiYe or all six of these agents with the ackive compound increases the wrinkle regulating benefits of the composition.
Methods for Requlatinq Wrinkles and/or Skin AtroPhY in Mammalian S_ The present invention relates to a mekhod for regulating wrinkles and/or atrophy in mammalian skin. Such a method com-prises treating the skin with a safe and effective amount of the active compound. The amount of active compound and frequenscy of treatment will vary widely depending upon the level of wrinkling and/or skin atrophy already in existence in the subject~ the rate of further wrinkle formation and/or atrophy, and the leYel of regulation desir~d.
A preferred method of treating the skin is via chronic topical application of a safe and effective amount of the active compound to regulate wrinkles andjor atrophy in mammalian skin.
The amount of ac~ive compound and frequency of topical application to the skin can vary widely, depending upon personal needs, but ~t is suggested as an exampl e that topical application range from about once per week to about ~lO times dsaily, pre~erably from a~out twice per week to about 4 times daily, more preferably from about 3 times a week to about 3 times daily, most preferably about once or twice per day. The composition for topical application will comprise from about 0.01% to about 50%, preferably from about 0.1%
1. I
to about~20Yc, more preferably from about 1% to about 10% of the active compound. By :"ehronic" application, it is meant hereiSn that the period of topical application may be over the lifetime of the subjeet, preferably for a perioa of at least about one month, more preferably from about three months to about twenty ySears~
more preferably from about six months to about ten years, more WO '33/04669 2 ~ 1~ 2 rJ~ 4; PCI/US92/072~7 preferably still from about one year to about fiYe years, thereby resulting in regulation of wrinkles and/or atrophy in mammalian s~i n .
A preferred method of the present invention for regulating wrinkles and/or atrophy in mamrnalian skin involves applying both a safe and effective amount of the active compound and a safe and ef~ective amount ~f one or more of a sunscreening agent, an anti-inflammatory agent, an anti-oxidant/radical scavenging agent, a chelating agent, a ret~noid and/ar a benzofuran der~vative to the skin simultaneously. As used herein, "simultaneous application'l or "simultaneously" means applying the agents to the skin at the same si~us on the body at about th~ same time. ~hough this can be accomplished by applying the agents separately to the skin, preferably a composition comprising all the desired agents cor~min-gled is applied to the skin. The amount of sunscreening agent applied is generally from about 0.02 ma to about 1.0 mg per cm2 skin. The amount of anti-inflamm2tory agent applied is generally from about ~.005 mg to ~bout 0.5 mg~ preferably from about 0.01 mg to about 0.1 m~ per cm2 skin. The amo~nt of anti-oxidant/radical scavenging agent generally applied is from about 0.001 mg to abo~t 1.0 mg, preferably from about 0.05 mg to abo~t 3.5 mg per cm2 skin. The amount of chelating agent generally applied is from awut 0.001 mg to about 1.0 mg, preferably from about 0.01 mg~to : ~ about 0.5 mg, more preferably from about 0.05 mg to ~bout 0.1 mg per cm2 skin. The a~ount of re~inoid applied is generally from about 0.00001 mg to about 0~02 mg per cm2 skin, preferably from about 0.001 mg to about ~.01 mg per cm2 skin. The amount of benzofuran derivative applied is generally from about 0.001 mg to about 1.0 mg/cm2 skin per application, preferably from about 0.01 to about O.S mg/cm2 skin per appiication. The amount of active compound applied is generaily from about 0.001 mg to abo~t 1.0 mg per cm2 skin per application, preferably ~rom about 0.01 mg to a~out 0.5 mg per cm2, more preferably from about 0.05 to about 0.25 m~/cm2 skin per appllcation.

21il~23~

The following examples further describë and demonstrate the preferred embodiments within the scope o~ the present invention The examples are given solely for the purpose of illustration, and are not to be construed as li~itations of the present invention since many variations thereof are possible without departing from its spirit and scope.
As used in the following examples, DMOM hydantoin is defined as 1,3-dimethylol-5,5-d;methyl hydantion.
EXAMPlE I
A topical comp~sition is prepared by combining the following components utilizing conventional mixing teehniques.
Comoonent Percent bY Weiqht Of CamDosition Distilled water 71.98 Disodi~m ethylenediaminetetraacetic acid (EDTA) 0.03 Glycerin 3.00 C~ s Alcohols Benzoate 6.00 ~lyceroliStearate 2.50 Stearjl alcohol 0.75 Cetyl alcohol ~ 1.00 DL-tocopherol 1.00 Polyoxyethylene~(12~ cètyl/stearyl ether (50:50) 0.50 Polyoxyethylene (20) cetyl/stearyl ether (50:50) 0.50 Talc 114 USP ~ 0.50 Butylene glycol 1.50 DM~M hydantoin/3-lodo-2-propynyl-bùtylcarbamate (95:5) 0.15 Sodium hydroxide ~20~ solution) 5.50 N-'acetyl-L-cysteine~
5.:00 ' .
Fragrance - Palmarose ;oil o.ag this composition is useful for topical application to regulate skin wrinkles and/or skin atrophy. Use of an amount of the composition to deposit about 2 mg/cm2 o~ the active compound to the skin is apprcpriate.
EXAMPLE II

'Ul~E SH~T

wo g3/046~9 Pc~rIUS92/07287 211~23~

A topical composition is prepared by combining the following components utilizing conventional mixing techniques.
Percent bY Wei~ht Component of ComDosition Distilled water 71.73 Disodium EDTA 0.03 Glycerin 3.00 C12-1s Alcohols Benzoate 6.00 Glycerol Stearate 2.50 Stearyl alcohol 0.75 Cetyl alcohol 1.00 DL-tocopherol 1. 00 Potyoxyethylene (12) cetyl/stearyl ether (5Q:S0) O.S0 Polyoxyethylene (20) cetyl/st~aryl ether (50:50) 0.50 Talc 114 USP 0~50 Butylene glycol 1.50 DMDM hydantoin/3-Iodo-2-propynyl-butylcarbamate (95:5) 0.15 Sodium hydroxide (Z0% solution) S.50 N-acetyl-L-cysteine 5.00 ~nCl2 ~ 0.25 Fragrance - Palmarose oil 0.09 This composition is useful for topical application to reg~-late skin wrinkles and/or~skin atrophy. Use of an amount of the composition sufficiant to deposit about 2 mg/cm2 of the active compound to the skin is~appropriate.
EXAMPLE III
A topical' composition is~ prepared by combining the fo1lowing components utilizing conven~lonal mixing techniques.

~: :

.

:

WO 93/0~669 PCI'/VS92/07287 21~ 3~

Percent bv Wei~ht Component of Composition Distilled water 69.98 Disodium EDTA - 0 03 Glycerin 3.00 C~ s A1cohols Benzoate 6.00 Glycerol Stearate 2.50 Stearyl alcohal 0.75 Cetyl alcohol I.00 ~L-tocopherol 1.~0 Polyoxyethylene (12) cetyl/stearyl ether (50:~0) 0.50 Polyoxyethyl ene (20) cetyl/stearyl ether (50:50) 0.50 Tal c 114 USP ~- 50 Butyl ene glycol 1. 50 DMDM hydantoin/3-Iodo-2-propynyl-butylcarbamate (95:5) 0.15 Sodium hydroxide ~20% solution) 5.50 N-acetyl-L-cysteine 5.00 Hydrocortisone 2.00 Fragrance - Palmarose oil 0.09 This composition is useful for topical application to regulate skin wrinkles and/or skin atrophy. Use of an amount Gf the compositian sufficient to deposit about 2 mg/cm2 of the act~ve compound to the skin is appropriata.
EXAMPLE IV
A sunscreen composition is prepared by combining the follow-ing components utilizing conventional mixing techniques.
Percent bY Weiqht ComDonent : of Com~osition Distilled water 61.73 Disodlum EDTA 0.03 Glycerin : 3.00 Cl2-ls Alcohols Benzaate 6.00 Glycerol Stearate 2.50 Stearyl alcohol 0.75 :

, : :

Wo ~3/04669 Pcr/US92/07287 2 ~ ~
z7 Cetyl alcohol 1.00 DL-tocopherol 1.00 Polyoxye~hylene (12) cetyl /stearyl ether (50:50) 0~50 Polyoxyethyl enR (20) cetyl/stearyl ether t50:50) 0~50 Talc 114 USP 0.50 Buty1 ene glycol 1 . Sû
DMDM hydantoin/3-lodo-2-propynyl-butylc~rbamate (95:5) 0.15 Sodium hydroxide (20% solution) 5.~0 N- acetyl - L -cystei ne S . OO
ZnO O . 25 Padimate O (octydimethyl p-aminobenzcic acid) 7,00 Butyldimethyldi benzoyl methane 3.00 Frangrance - Palmarose oil 0.09 This camposition is use~ul for topical appl ication to regulate skin wrinkles and/or skin atrophy, Use of an amount of the composition is suf~icient to deposit about 2 mg/cm2 o~ the active compound to the ski n i s: appropri ate .
N-acetyl -L-cysteine in the above Examples can be replaced with Zn-NAC or other active compounds of the structure provid~d herei n .
While particular embodiments of the subject invention have been described:, it will be. obvious to those skilled in the art that various changes and modifications of the subject invention can be made without departing from the spirit and scope of the inven~ion. :~It is intended to cover, in the appended claims, all such modi~ications that are within the scope of the invention.

:

Claims (9)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. The use of:
a) a safe and effective amount, preferably from 0.01% to 50%, more preferably from 0.1% to 20%, of N-acetyl-L-cysteine or a cosmetically-acceptable salt thereof; and b) a cosmetically-acceptable carrier, preferably a topical carrier, to make a cosmetic composition for regulating wrinkles or atrophy in mammalian skin.

2. The use of Claim 1 wherein the cosmetic composition is for chronic application, preferably for a period of at least six months comprising application of the composition from once per week to two times daily.

3. The use of Claim 1 wherein the cosmetic composition additionally comprises a safe and effective amount of a zinc salt, preferably the zinc salt is selected from the group consisting of zinc oxide, zinc stearate, zinc sulfate, zinc chloride and zinc acetate.

4. The use of Claim 2 wherein the cosmetic composition additionally comprises a safe and effective amount of a zinc salt, preferably the zinc salt is selected from the group consisting of zinc oxide, zinc stearate, zinc sulfate, zinc chloride and zinc acetate.

5. The use of Claim 1, 2, 3 or 4 wherein the cosmetic composition additionally comprises a safe and effective amount of a sunscreening agent.

6. The use of Claim 1, 2, 3 or 4 wherein the cosmetic composition additionallycomprises another active agent selected from the group consisting of a safe and effective amount of an anti-inflammatory agent, an anti-oxidant, a chelator, a retinoid, and a benzufuran derivative.

7. A composition useful for regulating wrinkles in mammalian skin which comprises N-acetyl-L-cysteine or a cosmetically acceptable salt thereof, a zinc salt, and a cosmetically-acceptable carrier.

8. A composition according to Claim 7 which comprises from 0.1 to 20% of N-acetyl-L-cysteine.

9. A composition according to Claim 7 wherein said zinc salt is zinc oxide, zincstearate, zinc sulfate, zinc chloride, zinc acetate or a mixture of two or more of these.